$GUTS

Royan Ajay purchased $20K of GUTS

Royan Ajay purchased 23,000 shares of FRACTYL HEALTH, INC. (GUTS) at $0.85 on 2026-06-12.

Original reporting
SEC EDGAR · Royan Ajay
Published Jun 15, 2026, 10:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GUTS
Bullish
low confidence
Mentioned
$GUTS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GUTSBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (date, shares, price, post-transaction holdings). This can slightly influence sentiment but does not introduce new operating or financial information.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

No 10b5-1 plan is noted, but the article provides no context on prior trading patterns, option exercises, or whether the buy is part of a broader accumulation strategy.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-15 after-hours; transaction dated 2026-06-12

Background

The article is an SEC Form 4 insider transaction disclosure for FRACTYL HEALTH, INC. (GUTS).

Company-level read

Ticker impact

$GUTSBullishLow confidence
Context

SEC Form 4 shows director Royan Ajay bought 23,000 shares of FRACTYL HEALTH (GUTS) at $0.8520 on 2026-06-12.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small for Form 4 buys.

Evidence & confidence

The filing is a routine insider transaction with no accompanying guidance, contract, or operational update; 10b5-1 is explicitly marked as no, but size is still modest relative to company-wide fundamentals.

Market effects

Minimal; this is company-specific insider activity with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may not reflect a change in fundamentals; they can also be driven by diversification or personal liquidity needs.

Key entities

  • FRACTYL HEALTH, INC.

    Company whose director insider transaction is disclosed on SEC Form 4.

  • Royan Ajay

    Director who purchased 23,000 shares at $0.8520 on 2026-06-12.

Related articles

MedAI 8/10

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Fractyl Health (

Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.

$GUTSMed

Fractyl's Revita Maintains Weight Loss Post GLP-1 Discontinuation; Stock Up

Fractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.

$GUTSMedAI 8/10

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.